 Adjuvants, Immunologic
"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Adjuvants, Immunological
- Immunological Adjuvants
- Immunological Adjuvant
- Adjuvant, Immunological
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunopotentiators
- Immunoactivators
- Immunoadjuvants
- Immunostimulants
- Immunologic Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in UAMS Profiles by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2017 | 1 | 1 | 2 | | 2014 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2011 | 4 | 2 | 6 | | 2010 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2003 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1997 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles over the past ten years.
-
Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.
-
Silva M, Kato Y, Melo MB, Phung I, Freeman BL, Li Z, Roh K, Van Wijnbergen JW, Watkins H, Enemuo CA, Hartwell BL, Chang JYH, Xiao S, Rodrigues KA, Cirelli KM, Li N, Haupt S, Aung A, Cossette B, Abraham W, Kataria S, Bastidas R, Bhiman J, Linde C, Bloom NI, Groschel B, Georgeson E, Phelps N, Thomas A, Bals J, Carnathan DG, Lingwood D, Burton DR, Alter G, Padera TP, Belcher AM, Schief WR, Silvestri G, Ruprecht RM, Crotty S, Irvine DJ. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Sci Immunol. 2021 Dec 03; 6(66):eabf1152.
-
Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
-
Rick J, Thompson AM, Hsiao JL, Liao W, Shi VY. Immunosuppressants, immunomodulators and COVID-19 vaccines: anticipating patient concerns. J Dermatolog Treat. 2022 05; 33(3):1794-1797.
-
Moyer TJ, Kato Y, Abraham W, Chang JYH, Kulp DW, Watson N, Turner HL, Menis S, Abbott RK, Bhiman JN, Melo MB, Simon HA, Herrera-De la Mata S, Liang S, Seumois G, Agarwal Y, Li N, Burton DR, Ward AB, Schief WR, Crotty S, Irvine DJ. Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat Med. 2020 03; 26(3):430-440.
-
Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020 Oct; 38(10):2537-2545.
-
Khoomrung S, Nookaew I, Sen P, Olafsdottir TA, Persson J, Moritz T, Andersen P, Harandi AM, Nielsen J. Metabolic Profiling and Compound-Class Identification Reveal Alterations in Serum Triglyceride Levels in Mice Immunized with Human Vaccine Adjuvant Alum. J Proteome Res. 2020 01 03; 19(1):269-278.
-
Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017 11; 31(11):2443-2448.
-
Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017 03 14; 35(12):1586-1589.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|